Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...
Seres Therapeutics Inc (MCRB) reports promising clinical results and strategic financial maneuvers, despite facing increased ...
Seres reports Q3 EPS from continuing operations (33c), consensus (24c)
As of September 30, Seres Therapeutics (MCRB) had $66.8M in cash and cash equivalents. The company expects to fund operations into Q4 of 2025.
Business Insider20h
Correction: Seres reports Q3 EPS from continuing operations (33c)
Try Now>> See today’s best-performing stocks on TipRanks >> Read More on MCRB: Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success Seres Therapeutics reports Q3 EPS 58c, consensus (24c) Seres ...
Times Union23h
Seres Therapeutics: Q3 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Seres Therapeutics Inc. (MCRB) on Wednesday reported third-quarter earnings of $88.8 million. The Cambridge, Massachusetts-based company said it had ...
TMCnet23h
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported third quarter 2024 financial ...